These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 11818362)

  • 21. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
    Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
    Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis.
    Paul R; Winkler F; Bayerlein I; Popp B; Pfister HW; Koedel U
    J Infect Dis; 2005 Mar; 191(5):776-82. PubMed ID: 15688295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
    Türkmen B; Schmitt M; Schmalfeldt B; Trommler P; Hell W; Creutzburg S; Graeff H; Magdolen V
    Electrophoresis; 1997 May; 18(5):686-9. PubMed ID: 9194591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice.
    Wang H; Vohra BP; Zhang Y; Heuckeroth RO
    Hepatology; 2005 Nov; 42(5):1099-108. PubMed ID: 16250054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
    Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
    Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor.
    Prager GW; Breuss JM; Steurer S; Olcaydu D; Mihaly J; Brunner PM; Stockinger H; Binder BR
    Circ Res; 2004 Jun; 94(12):1562-70. PubMed ID: 15131009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
    Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
    Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The plasminogen-activating system in hepatic stellate cells.
    Leyland H; Gentry J; Arthur MJ; Benyon RC
    Hepatology; 1996 Nov; 24(5):1172-8. PubMed ID: 8903394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage.
    Knier B; Cordasic N; Klanke B; Heusinger-Ribeiro J; Daniel C; Veelken R; Hartner A; Hilgers KF
    J Hypertens; 2011 Aug; 29(8):1602-12. PubMed ID: 21610512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development.
    Teesalu T; Blasi F; Talarico D
    Dev Dyn; 1998 Sep; 213(1):27-38. PubMed ID: 9733098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
    Bajou K; Masson V; Gerard RD; Schmitt PM; Albert V; Praus M; Lund LR; Frandsen TL; Brunner N; Dano K; Fusenig NE; Weidle U; Carmeliet G; Loskutoff D; Collen D; Carmeliet P; Foidart JM; Noël A
    J Cell Biol; 2001 Feb; 152(4):777-84. PubMed ID: 11266468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta.
    Hertig A; Berrou J; Allory Y; Breton L; Commo F; Costa De Beauregard MA; Carmeliet P; Rondeau E
    FASEB J; 2003 Oct; 17(13):1904-6. PubMed ID: 12897066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasminogen activator inhibitor-1 in kidney pathology (Review).
    Małgorzewicz S; Skrzypczak-Jankun E; Jankun J
    Int J Mol Med; 2013 Mar; 31(3):503-10. PubMed ID: 23314920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression.
    Lee H; Struman I; Clapp C; Martial J; Weiner RI
    Endocrinology; 1998 Sep; 139(9):3696-703. PubMed ID: 9724020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.